16:08 EST Jazz Pharmaceuticals (JAZZ) sees FY26 revenue $4.25B-$4.5B, consensus $4.5B
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- JAZZ Earnings this Week: How Will it Perform?
- ALX Oncology announces new data from Phase 1b/2 trial of evorpacept, Ziihera
- Jazz Pharmaceuticals price target raised to $220 from $205 at TD Cowen
- Jazz Pharmaceuticals price target raised to $230 from $220 at Truist
- Jazz Pharmaceuticals price target raised to $235 from $210 at Needham